|Target disease||Neuropathic pain after shingles|
|Development stage||Filed NDA application in U.S.|
|Collaborative development company||MEDRx Co., Ltd.|
|Overview||DW-5LBT（MRX-5LBT） is a new type of lidocaine patch for the treatment of post-herpetic neuralgia that uses the ILTS® (lonic Liquid Transdermal System), an exclusive MEDRx technology incorporating the company’s ionic liquid expertise. DW-5LBT is being developed with the goal of targeting the market for Lidoderm®, a lidocaine patch.
In April 2020, we conducted collaborative development agreement with MEDRx. From now on, we will work with MEDRx to develop and commercialize the DW-5LBT（MRX-5LBT） in the United States.
|2020||Apr.||Conducted collaborative development agreement with MEDRx.|
|Aug.||Filed NDA application in U.S.|